NCT07386210Completed
Antihypertensive Effects of Rosmarinus Officinalis L. Infusion
Antihypertensive Effects of Rosmarinus Officinalis L. Infusion Supplements in Male Patients With Mild Hypertension : A Randomized Double-Blind Placebo-Controlled Study
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
This study assessed the antihypertensive effect of rosemary tea through a placebo-controlled clinical study, angiotensin-converting enzyme (ACE) inhibition analysis, and in silico evaluation of interactions between rosemary bioactive compounds and the AT1R (Angiotensin II Type 1 Receptor). A randomized, double-blind, placebo-controlled trial was conducted in 54 male patients with mild hypertension. Participants were assigned to receive either rosemary infusion (n = 27) or placebo (n = 23) for 45 days. Ambulatory blood pressure monitoring wass used to evaluate blood pressure parameters. Serum ACE activity was measured at baseline and after the intervention using FAPGG hydrolysis. Molecular docking simulations were performed using the Dock 4.2 software.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 54 (actual)
- First submitted
- 11 Jan 2026
- Start date
- 20 Mar 2023
- Primary completion date
- 28 Aug 2025
- Lead sponsor
- awatef Sassi
- Diseases
- High blood pressure
- NCT number
- NCT07386210
What you commit to
- Study type: Interventional
- Participants enrolled: 54
- From 20 Mar 2023 to the primary completion date, 28 Aug 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of medications affecting blood pressure
- Significant dietary changes or irregular physical activity in the previous six months
- Alcohol consumption or use of illicit drugs
Other illness
- Secondary hypertension
- History of cardiovascular disease, diabetes mellitus, renal failure, autoimmune disease, or major gastrointestinal disorders
Other
- Extreme body mass index (BMI) values
- Inability or unwillingness to maintain usual diet and lifestyle during the study
Who the study is looking for
- Male participants aged 28-65 years
- Mild hypertension, defined as systolic blood pressure (SBP) 140-159 mmHg and/or diastolic blood pressure (DBP) 90-99 mmHg, according to ESC/ESH 2018 guidelines
- No history of chronic diseases
- Not currently taking antihypertensive medications, other drugs, or dietary supplements
- Body mass index (BMI) within the screening range at recruitment
- Provided written informed consent
Age in the registry: 18 years to 65 years · Sex: Male · Accepts healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine of Sousse Coordinator of this site? Confirm its status | Sousse | Tunisia | Unknown status |
| Sassi Coordinator of this site? Confirm its status | Sousse | Tunisia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.